Terns Pharmaceuticals Inc [TERN] stock is trading at $10.02, down -0.20%. An important factor to consider is whether the stock is rising or falling in short-term value. The TERN shares have gain 11.89% over the last week, with a monthly amount glided 27.16%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Terns Pharmaceuticals Inc [NASDAQ: TERN] stock has seen the most recent analyst activity on June 22, 2023, when Mizuho initiated its Buy rating and assigned the stock a price target of $16. Previously, Jefferies started tracking the stock with Buy rating on June 07, 2023, and set its price target to $18. On May 31, 2023, ROTH MKM initiated with a Buy rating and assigned a price target of $23 on the stock. BMO Capital Markets started tracking the stock assigning a Outperform rating and suggested a price target of $18 on May 08, 2023. JMP Securities initiated its recommendation with a Mkt Outperform and recommended $17 as its price target on February 14, 2023. UBS started tracking with a Buy rating for this stock on February 07, 2023, and assigned it a price target of $19. In a note dated September 12, 2022, H.C. Wainwright initiated an Neutral rating and provided a target price of $6 on this stock.
Terns Pharmaceuticals Inc [TERN] stock has fluctuated between $3.26 and $11.40 over the past year. Currently, Wall Street analysts expect the stock to reach $14.25 within the next 12 months. Terns Pharmaceuticals Inc [NASDAQ: TERN] shares were valued at $10.02 at the most recent close of the market. An investor can expect a potential return of 42.22% based on the average TERN price forecast.
Analyzing the TERN fundamentals
Gross Profit Margin for this corporation currently stands at 0.31% with Operating Profit Margin at -81.86%, Pretax Profit Margin comes in at -72.34%, and Net Profit Margin reading is -72.54%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -0.4 and Total Capital is -0.49. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.73 points at the first support level, and at 9.44 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.50, and for the 2nd resistance point, it is at 10.98.
Ratios To Look Out For
For context, Terns Pharmaceuticals Inc’s Current Ratio is 21.02. On the other hand, the Quick Ratio is 21.02, and the Cash Ratio is 8.35.
Transactions by insiders
Recent insider trading involved Lu Hongbo, Director, that happened on Sep 12 ’24 when 0.48 million shares were purchased. Chief Financial Officer, Vignola Mark J. completed a deal on Sep 10 ’24 to sell 10000.0 shares. Meanwhile, Director Quigley Jill M. sold 17235.0 shares on Sep 09 ’24.
